Funding for this research was provided by:
European Commission (341196)
Received: 4 June 2021
Accepted: 8 December 2021
First Online: 31 December 2021
: All research on human subjects reported in this manuscript was prospectively approved by the Institutional Review Board of Hospital Vall d’Hebron, Hospital del Mar i l’Esperança from Barcelona, and Hospital Joan XXIII from Tarragona and all participants provided written informed consent.
: Not applicable.
: P. F. M. J. Verschure leads the research group SPECS that developed RGS, and is the CEO/founder of the spin-off company Eodyne Systems, SL, which commercialises RGS with the goal to achieve a large-scale distribution of low-cost science-based rehabilitation technologies.